• Renee R Koski and Kirsten M Grzegorczyk.
• Pharmacy Practice, Ferris State University College of Pharmacy, Marquette, MI, USA.
• J Pharm Pract. 2020 Aug 1; 33 (4): 513-522.

ObjectiveTo summarize the current literature for Food and Drug Administration (FDA)-approved monoclonal antibodies used as add-on maintenance therapy in uncontrolled eosinophilic asthma.Data SourcesPubMed was searched on December 17, 2018 using keywords: asthma, eosinophilic asthma, omalizumab, reslizumab, mepolizumab, benralizumab, and dupilumab.Study SelectionStudies evaluating safety and efficacy of monoclonal antibodies for treatment of severe or eosinophilic asthma were included.ResultsTwenty-one randomized, double-blind, placebo-controlled trials evaluating the current FDA-approved monoclonal antibodies (omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab) for the treatment of uncontrolled eosinophilic asthma were included. The studies demonstrated clinically significant reductions in asthma exacerbations, symptoms, emergency room visits, eosinophil counts, and improvements in pulmonary function and asthma-related quality of life.ConclusionFive monoclonal antibodies are available for uncontrolled eosinophilic asthma. Choice depends on patient factors. Future studies should focus on cost-effectiveness of treatment, drug-drug comparisons, and long-term efficacy and safety.

15 keywords...

hide…